The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy
Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba ®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorpt...
Gespeichert in:
| Veröffentlicht in: | Transfusion and apheresis science 2001-02, Vol.24 (1), p.95-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 95 |
| container_title | Transfusion and apheresis science |
| container_volume | 24 |
| creator | Schneidewind, J.M Zettl, U.K Winkler, R.E Ramlow, W Tiess, M Michelsen, A Hebestreit, G Prophet, H Pätow, W Benecke, R |
| description | Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba
®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorption treatments have been carried out. In addition, three patients were given a thymectomy. The present status of the patients was checked six and eight years thereafter. We could see a beneficial effect in all MG patients. The patients are fit for work; all have an improved Besinger index. The patients were used as their own controls. A higher anti-AChR-ab level six years after protein A immunoabsorption than at the beginning was seen in all patients combined with a less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoabsorption treatment. A larger population has to be investigated to verify these results. |
| doi_str_mv | 10.1016/S0955-3886(00)00125-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71107386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0955388600001259</els_id><sourcerecordid>71107386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-96e95e971d8594504ff5bdceb629aabae28d7203d9c0de05af62b2a185accd9d3</originalsourceid><addsrcrecordid>eNqFkM9u1DAQhyNERUvhEUA-ITi42MnasU-oqvgnVeJAOVsTe7JrlNjBdor21nfoG_IkuN2VOHKaGen7zWi-pnnF2QVnXL7_zrQQtFNKvmXsHWO8FVQ_ac646hXlUnVPa7_pO8oEa0-b5zn_rFDPtXzWnHIuuJBcnzXhZockrsXGGYkPZN5DLjsMHsg2wa3PZIHiMZRM_tzdEwgE_XZX6B4hkTFOU_xN14XAWLDOPvi882FL_DyvIcKQY1qKj4HUnQmW_YvmZIQp48tjPW9-fPp4c_WFXn_7_PXq8praTvJCtUQtUPfcKaE3gm3GUQzO4iBbDTAAtsr1LeuctswhEzDKdmiBKwHWOu268-bNYe-S4q8VczGzzxanCQLGNZuec9Z3SlZQHECbYs4JR7MkP0PaG87Mg2jzKNo8iDaMmUfRRtfc6-OBdZjR_UsdzVbgwwHA-uatx2SyrR4tOp_QFuOi_8-Jv5vckTU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71107386</pqid></control><display><type>article</type><title>The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Schneidewind, J.M ; Zettl, U.K ; Winkler, R.E ; Ramlow, W ; Tiess, M ; Michelsen, A ; Hebestreit, G ; Prophet, H ; Pätow, W ; Benecke, R</creator><creatorcontrib>Schneidewind, J.M ; Zettl, U.K ; Winkler, R.E ; Ramlow, W ; Tiess, M ; Michelsen, A ; Hebestreit, G ; Prophet, H ; Pätow, W ; Benecke, R</creatorcontrib><description>Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba
®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorption treatments have been carried out. In addition, three patients were given a thymectomy. The present status of the patients was checked six and eight years thereafter. We could see a beneficial effect in all MG patients. The patients are fit for work; all have an improved Besinger index. The patients were used as their own controls. A higher anti-AChR-ab level six years after protein A immunoabsorption than at the beginning was seen in all patients combined with a less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoabsorption treatment. A larger population has to be investigated to verify these results.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>DOI: 10.1016/S0955-3886(00)00125-9</identifier><identifier>PMID: 11515619</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Antibodies - blood ; Blood Component Removal - methods ; Female ; Follow-Up Studies ; Health technology assessment ; Humans ; Immunoabsorption ; Immunosorbent Techniques ; Lymphocytes ; Male ; Middle Aged ; Muscle, Skeletal - immunology ; Myasthenia gravis ; Myasthenia Gravis - therapy ; Protein A ; Receptors, Cholinergic - immunology ; Salvage Therapy ; Staphylococcal Protein A - therapeutic use ; Therapeutic apheresis ; Thymoma ; Treatment Outcome</subject><ispartof>Transfusion and apheresis science, 2001-02, Vol.24 (1), p.95-98</ispartof><rights>2001 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-96e95e971d8594504ff5bdceb629aabae28d7203d9c0de05af62b2a185accd9d3</citedby><cites>FETCH-LOGICAL-c361t-96e95e971d8594504ff5bdceb629aabae28d7203d9c0de05af62b2a185accd9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0955388600001259$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11515619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schneidewind, J.M</creatorcontrib><creatorcontrib>Zettl, U.K</creatorcontrib><creatorcontrib>Winkler, R.E</creatorcontrib><creatorcontrib>Ramlow, W</creatorcontrib><creatorcontrib>Tiess, M</creatorcontrib><creatorcontrib>Michelsen, A</creatorcontrib><creatorcontrib>Hebestreit, G</creatorcontrib><creatorcontrib>Prophet, H</creatorcontrib><creatorcontrib>Pätow, W</creatorcontrib><creatorcontrib>Benecke, R</creatorcontrib><title>The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba
®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorption treatments have been carried out. In addition, three patients were given a thymectomy. The present status of the patients was checked six and eight years thereafter. We could see a beneficial effect in all MG patients. The patients are fit for work; all have an improved Besinger index. The patients were used as their own controls. A higher anti-AChR-ab level six years after protein A immunoabsorption than at the beginning was seen in all patients combined with a less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoabsorption treatment. A larger population has to be investigated to verify these results.</description><subject>Adult</subject><subject>Antibodies - blood</subject><subject>Blood Component Removal - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Immunoabsorption</subject><subject>Immunosorbent Techniques</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle, Skeletal - immunology</subject><subject>Myasthenia gravis</subject><subject>Myasthenia Gravis - therapy</subject><subject>Protein A</subject><subject>Receptors, Cholinergic - immunology</subject><subject>Salvage Therapy</subject><subject>Staphylococcal Protein A - therapeutic use</subject><subject>Therapeutic apheresis</subject><subject>Thymoma</subject><subject>Treatment Outcome</subject><issn>1473-0502</issn><issn>1878-1683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9u1DAQhyNERUvhEUA-ITi42MnasU-oqvgnVeJAOVsTe7JrlNjBdor21nfoG_IkuN2VOHKaGen7zWi-pnnF2QVnXL7_zrQQtFNKvmXsHWO8FVQ_ac646hXlUnVPa7_pO8oEa0-b5zn_rFDPtXzWnHIuuJBcnzXhZockrsXGGYkPZN5DLjsMHsg2wa3PZIHiMZRM_tzdEwgE_XZX6B4hkTFOU_xN14XAWLDOPvi882FL_DyvIcKQY1qKj4HUnQmW_YvmZIQp48tjPW9-fPp4c_WFXn_7_PXq8praTvJCtUQtUPfcKaE3gm3GUQzO4iBbDTAAtsr1LeuctswhEzDKdmiBKwHWOu268-bNYe-S4q8VczGzzxanCQLGNZuec9Z3SlZQHECbYs4JR7MkP0PaG87Mg2jzKNo8iDaMmUfRRtfc6-OBdZjR_UsdzVbgwwHA-uatx2SyrR4tOp_QFuOi_8-Jv5vckTU</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Schneidewind, J.M</creator><creator>Zettl, U.K</creator><creator>Winkler, R.E</creator><creator>Ramlow, W</creator><creator>Tiess, M</creator><creator>Michelsen, A</creator><creator>Hebestreit, G</creator><creator>Prophet, H</creator><creator>Pätow, W</creator><creator>Benecke, R</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010201</creationdate><title>The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy</title><author>Schneidewind, J.M ; Zettl, U.K ; Winkler, R.E ; Ramlow, W ; Tiess, M ; Michelsen, A ; Hebestreit, G ; Prophet, H ; Pätow, W ; Benecke, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-96e95e971d8594504ff5bdceb629aabae28d7203d9c0de05af62b2a185accd9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antibodies - blood</topic><topic>Blood Component Removal - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Immunoabsorption</topic><topic>Immunosorbent Techniques</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle, Skeletal - immunology</topic><topic>Myasthenia gravis</topic><topic>Myasthenia Gravis - therapy</topic><topic>Protein A</topic><topic>Receptors, Cholinergic - immunology</topic><topic>Salvage Therapy</topic><topic>Staphylococcal Protein A - therapeutic use</topic><topic>Therapeutic apheresis</topic><topic>Thymoma</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schneidewind, J.M</creatorcontrib><creatorcontrib>Zettl, U.K</creatorcontrib><creatorcontrib>Winkler, R.E</creatorcontrib><creatorcontrib>Ramlow, W</creatorcontrib><creatorcontrib>Tiess, M</creatorcontrib><creatorcontrib>Michelsen, A</creatorcontrib><creatorcontrib>Hebestreit, G</creatorcontrib><creatorcontrib>Prophet, H</creatorcontrib><creatorcontrib>Pätow, W</creatorcontrib><creatorcontrib>Benecke, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schneidewind, J.M</au><au>Zettl, U.K</au><au>Winkler, R.E</au><au>Ramlow, W</au><au>Tiess, M</au><au>Michelsen, A</au><au>Hebestreit, G</au><au>Prophet, H</au><au>Pätow, W</au><au>Benecke, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>24</volume><issue>1</issue><spage>95</spage><epage>98</epage><pages>95-98</pages><issn>1473-0502</issn><eissn>1878-1683</eissn><abstract>Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba
®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorption treatments have been carried out. In addition, three patients were given a thymectomy. The present status of the patients was checked six and eight years thereafter. We could see a beneficial effect in all MG patients. The patients are fit for work; all have an improved Besinger index. The patients were used as their own controls. A higher anti-AChR-ab level six years after protein A immunoabsorption than at the beginning was seen in all patients combined with a less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoabsorption treatment. A larger population has to be investigated to verify these results.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>11515619</pmid><doi>10.1016/S0955-3886(00)00125-9</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2001-02, Vol.24 (1), p.95-98 |
| issn | 1473-0502 1878-1683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71107386 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Antibodies - blood Blood Component Removal - methods Female Follow-Up Studies Health technology assessment Humans Immunoabsorption Immunosorbent Techniques Lymphocytes Male Middle Aged Muscle, Skeletal - immunology Myasthenia gravis Myasthenia Gravis - therapy Protein A Receptors, Cholinergic - immunology Salvage Therapy Staphylococcal Protein A - therapeutic use Therapeutic apheresis Thymoma Treatment Outcome |
| title | The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T23%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20outcome%20in%20myasthenia%20gravis%20patients%20%E2%80%93%20an%20eight-year%20follow-up%20after%20finishing%20immunoabsorption%20therapy&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Schneidewind,%20J.M&rft.date=2001-02-01&rft.volume=24&rft.issue=1&rft.spage=95&rft.epage=98&rft.pages=95-98&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/S0955-3886(00)00125-9&rft_dat=%3Cproquest_cross%3E71107386%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71107386&rft_id=info:pmid/11515619&rft_els_id=S0955388600001259&rfr_iscdi=true |